Stock Analysis
As the Chinese market navigates through mixed economic signals and a backdrop of global uncertainty, investors are increasingly focused on identifying resilient growth opportunities. One key indicator of potential long-term success is high insider ownership, which often aligns management's interests with those of shareholders and can signal confidence in a company's future prospects.
Top 10 Growth Companies With High Insider Ownership In China
Name | Insider Ownership | Earnings Growth |
Ningbo Sunrise Elc TechnologyLtd (SZSE:002937) | 24.3% | 27.7% |
ShenZhen Woer Heat-Shrinkable MaterialLtd (SZSE:002130) | 19% | 27.9% |
Arctech Solar Holding (SHSE:688408) | 38.7% | 28.4% |
Cubic Sensor and InstrumentLtd (SHSE:688665) | 10.1% | 34.3% |
KEBODA TECHNOLOGY (SHSE:603786) | 12.8% | 25.1% |
Xi'an Sinofuse Electric (SZSE:301031) | 36.8% | 43.1% |
Suzhou Sunmun Technology (SZSE:300522) | 36.5% | 63.4% |
Eoptolink Technology (SZSE:300502) | 26.7% | 39.4% |
Sineng ElectricLtd (SZSE:300827) | 36.5% | 39.8% |
UTour Group (SZSE:002707) | 23% | 36.1% |
We're going to check out a few of the best picks from our screener tool.
Guangdong Create Century Intelligent Equipment Group (SZSE:300083)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Guangdong Create Century Intelligent Equipment Group Corporation Limited, with a market cap of CN¥9.27 billion, specializes in the research, development, production, and sale of high-end intelligent equipment in China.
Operations: The company's revenue segments include the research, development, production, and sale of high-end intelligent equipment in China.
Insider Ownership: 18.6%
Guangdong Create Century Intelligent Equipment Group's revenue is forecast to grow 25.8% annually, significantly outpacing the Chinese market's 13.6%. Despite this, profit margins have declined from 6.6% to 4.1%, and the share price has been highly volatile over the past three months. The company's earnings are expected to grow at a robust rate of 41.2% per year, although its Return on Equity is projected to be relatively low at 10.7% in three years' time.
- Click here and access our complete growth analysis report to understand the dynamics of Guangdong Create Century Intelligent Equipment Group.
- Our valuation report unveils the possibility Guangdong Create Century Intelligent Equipment Group's shares may be trading at a premium.
PharmaBlock Sciences (Nanjing) (SZSE:300725)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: PharmaBlock Sciences (Nanjing), Inc. offers chemistry products and services for pharmaceutical research, development, and commercial production, with a market cap of CN¥6.09 billion.
Operations: PharmaBlock Sciences (Nanjing) generates CN¥1.72 billion from its drug research, development, and production-related business.
Insider Ownership: 25%
PharmaBlock Sciences (Nanjing) is poised for significant earnings growth, forecasted at 25.7% per year, outpacing the Chinese market's 22.2%. Revenue is expected to grow at 16.1% annually, also ahead of the market's 13.6%. Despite a recent decline in profit margins from 18.3% to 11%, the company has high insider ownership and recently increased its dividend payout to CNY 3.10 per share for 2023, payable on June 14, 2024.
- Click to explore a detailed breakdown of our findings in PharmaBlock Sciences (Nanjing)'s earnings growth report.
- Our expertly prepared valuation report PharmaBlock Sciences (Nanjing) implies its share price may be too high.
Ginlong Technologies (SZSE:300763)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Ginlong Technologies Co., Ltd. is involved in the global research, development, production, service, and sale of string inverters with a market cap of CN¥25.85 billion.
Operations: Ginlong Technologies' revenue segments include CN¥2.50 billion from domestic sales and CN¥1.70 billion from international sales, totaling CN¥4.20 billion.
Insider Ownership: 38.1%
Ginlong Technologies is forecasted to achieve significant earnings growth, estimated at 25.72% annually, surpassing the Chinese market's 22.2%. Revenue is expected to grow at 18.2% per year, outpacing the market's 13.6%. Despite a reduction in profit margins from 18.9% to 8.1%, the company maintains high insider ownership and has not diluted shareholders over the past year, although its share price has been highly volatile recently.
- Take a closer look at Ginlong Technologies' potential here in our earnings growth report.
- The analysis detailed in our Ginlong Technologies valuation report hints at an inflated share price compared to its estimated value.
Seize The Opportunity
- Navigate through the entire inventory of 358 Fast Growing Chinese Companies With High Insider Ownership here.
- Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Curious About Other Options?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SZSE:300725
PharmaBlock Sciences (Nanjing)
Provides chemistry products and services throughout the pharmaceutical research and development, and commercial production.